Vincent Picozzi is an Oncology physician affiliated with Virginia Mason Medical Center. OpenAlex indexes 264 publications with 7,489 citations (h-index 39); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1100 9th Ave
Seattle, WA 981012756
Telephone
206-223-6600Registry record last updated 17 Jun 2008.
Clinical trials
- Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology
Sponsor: Benaroya Research Institute
- Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Sponsor: Benaroya Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year202524 payments
- Novocure GmbHProgram year20251 payment
- Verastem, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
42%Antidiarrheal microorganisms19.5%Creon91%Zenpep9%Part D<11 patientsSerotonin-3 Receptor Antagonist6.4%Ondansetron Hcl71%Ondansetron Odt29%Part D≥40 patients+ 6 more classes in this area
Nervous system
19.8%Opioid Agonist6%Oxycodone Hcl69%Oxycodone-Acetaminophen18%Fentanyl14%Part D<11 patientsGabapentinoids4.1%Gabapentin100%Part D≥19 patients+ 4 more classes in this area
Blood & clotting
12.7%Low Molecular Weight Heparin10.8%Enoxaparin Sodium100%Part D≥26 patientsFactor Xa inhibitor1.9%Xarelto100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop
Journal of Cachexia Sarcopenia and Muscle
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Donald Low, MD
Virginia Mason Medical Center
Richard Kozarek, MD
Virginia Mason Medical Center
David Aboulafia, MD
Virginia Mason Medical Center
Neil Hampson, MD
Virginia Mason Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”